Tikcro Technologies Ltd. (Tikcro) provides funding for early-stage biotechnology projects with a focus on oncology. The Company provides funding for early-stage biotechnology projects originating in Israeli academic centers. The Company's product candidate antibodies focuses on blocking the ligand/receptor linkage of certain biological pathways, specifically antibodies that block anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1), and by blocking these pathways to prevent the inhibition of patients' self immune system and its ability to attack cancerous cells. The Company focuses on antibody drug-candidates that block the binding surface domain and do not block adjacent domains. The Company's project focuses on the immune system pathways, which include CTLA-4 and its binding group of ligands; PD-1 and ligands PDL-1 and PDL-2, and T cell immunoreceptor with Ig and ITIM domains (TIGIT) and its binding group of ligands.